JAZZ
NASDAQ · Pharmaceuticals
Jazz Pharmaceuticals Plc
$189.08
+4.07 (+2.20%)
Financial Highlights (FY 2026)
Revenue
3.73B
Net Income
514.09M
Gross Margin
89.0%
Profit Margin
13.8%
Rev Growth
+9.6%
D/E Ratio
1.49
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 89.0% | 89.0% | 35.9% | 35.9% |
| Operating Margin | 17.6% | 15.8% | 25.1% | 26.2% |
| Profit Margin | 13.8% | 13.1% | 28.9% | 24.4% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 3.73B | 3.41B | 1.73B | 1.70B |
| Gross Profit | 3.33B | 3.04B | 622.43M | 609.30M |
| Operating Income | 657.65M | 540.24M | 435.37M | 444.25M |
| Net Income | 514.09M | 422.31M | 500.28M | 414.07M |
| Gross Margin | 89.0% | 89.0% | 35.9% | 35.9% |
| Operating Margin | 17.6% | 15.8% | 25.1% | 26.2% |
| Profit Margin | 13.8% | 13.1% | 28.9% | 24.4% |
| Rev Growth | +9.6% | +9.6% | +7.8% | +14.0% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 3.08B | 3.08B | 3.35B | 3.35B |
| Total Equity | 2.06B | 2.06B | 6.96B | 7.49B |
| D/E Ratio | 1.49 | 1.49 | 0.48 | 0.45 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 1.23B | 1.07B | 730.31M | 605.53M |
| Free Cash Flow | — | — | 376.40M | 328.43M |